BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target
BTIG analyst Julian Harrison reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $4 price target.
Read original at benzingaStocks · News reference
Outlook Therapeutics Says FDA Approves LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration, Commonly Known As Wet AMD
Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 24, 2026, 6:41 PM
- Checked
- Jul 24, 2026, 6:41 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
Read original at benzingaOutlook Therapeutics shares are trading lower after the company reported worse-than-expected Q3 sales results.
Read original at benzingaTranscript: Outlook Therapeutics Q3 2026 Earnings Conference Call
Outlook Therapeutics (NASDAQ:OTLK) released third-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time
Read original at benzinga